🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonis...
Status
Completed
Location
GSK Investigational Site
Start Date
2016-06-23
Trial ID
NCT02723955
This study is a randomized controlled, open-label, multicenter phase III cl...
Status
Recruiting
Location
Erwei Song
Start Date
2023-12-01
Trial ID
NCT06079983
Phase II: To evaluate the safety and tolerability of IAE0972 combined with ...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2025-01-01
Trial ID
NCT06719479
Treatments Being Tested
CDK4/6 inhibitors are currently the standard treatment for female breast ca...
Status
Unknown
Location
Peking Union Medical College Hospital
Start Date
2023-05-15
Trial ID
NCT05861830
The purpose of this randomized clinical study is to confirm the utility of ...
Status
Withdrawn
Location
Univeristy of Mississippi Medical Center
Start Date
2018-08-01
Trial ID
NCT03632798
Treatments Being Tested
This is an international, randomized, open-label, Phase 3 study designed to...
Status
Terminated
Location
Hospital Britanico
Start Date
2020-07-24
Trial ID
NCT04222972
Treatments Being Tested
The purpose of this study is to evaluate the efficacy and safety of pertuzu...
Status
Completed
Location
Aichi Cancer Center
Start Date
2015-08-01
Trial ID
NCT02514681
This is an open-label, Single-arm, Phase I clinical study to evaluate the p...
Status
Completed
Location
The fifth medical center of the General Hospital of people's Liberation Army of China
Start Date
2020-08-25
Trial ID
NCT04398108
Treatments Being Tested
This is a Phase III clinical trial for patients with a specific type of adv...
Status
Active Not Recruiting
Location
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Start Date
2024-06-12
Trial ID
NCT07371910
Treatments Being Tested
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER...
Status
Unknown
Location
Fudan University Shanghai Cancer Center
Start Date
2021-09-15
Trial ID
NCT05346861
Treatments Being Tested